Amarillo, Texas, July 11, 2011 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that the treatment phase in its Phase 2 dose-ranging clinical trial of 169 hepatitis C patients has been completed. Subjects were given low-dose oral interferon or placebo for 24 weeks to judge the effect on the relapse rate in hepatitis C patients who achieved virologic remission after treatment with Ribavirin and high-dose injectable interferon. The treatments will be unblinded after subjects complete a 6-month untreated observation period, with final results expected in early 2012. Currently, there are no FDA-approved products for preventing relapse in hepatitis C patients after initial treatment. Relapse can be as high as 60% with some genotypes of hepatitis C virus, so a product that reduces the relapse rate will address a major unmet medical need.
ABI is actively seeking funding for oral interferon research in the area of viral respiratory diseases as a follow-up to positive findings from the company’s flu treatment and prevention study conducted in Australia. One planned target of study is the annual Hajj pilgrimage, during which millions of Muslims travel from 120 countries to Mecca and Medina in Saudi Arabia. The congregation of these pilgrims from many different countries results in widespread symptomatic respiratory tract infections, which puts a tremendous strain on Saudi Arabia’s medical facilities. “Our product offers a possible solution to this critical problem because animal studies have shown that low-dose oral interferon reduces the severity and duration of viral respiratory tract disease during comingling,” stated Dr. Joseph M. Cummins, President and CEO of ABI.
In other developments, the company has engaged Interactive Business Alliance, LLC of San Diego to help with public relations and communications services. Moreover, KracklePop Design of Roswell, New Mexico has been engaged to help create the branding for ABI’s new dietary supplement that promotes health and enhances immunity, which is to be launched later this year.
About Amarillo Biosciences
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 6% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at http://www.amarbio.com/.
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company’s other product candidates and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In particular, see “Item 1. Description of Business” and “Item 7A. Qualitative and Quantitative Disclosures About Market Risk” of the Company’s Form 10-K for the fiscal year ended December 31, 2010. --END--